Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
Arvinas, a clinical-stage biotechnology firm listed on Nasdaq under the symbol ARVN, announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference scheduled for June 13 at 4:20 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arvinas, a clinical-stage biotechnology firm listed on Nasdaq under the symbol ARVN, announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference scheduled for June 13 at 4:20 p.m. ET. The event will feature a fireside chat with the company's management in Rancho Palos Verdes, California. A live audio webcast will be available on the company's website. Arvinas focuses on developing therapies that degrade disease-causing proteins, utilizing its proprietary PROTAC® technology, with ongoing clinical programs targeting prostate and breast cancer.
Details
News Market Reaction – ARVN
The recorded move for ARVN in the trading session of this news was +3.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13 at 4:20 p.m. ET / 1:20 p.m. PT in Rancho Palos Verdes, Calif.
A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts
Investors:
Jeff Boyle
347-247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
203-584-0307
Kirsten.Owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.